Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2762 - Cabozantinib for the treatment of patients with metastatic variant histology renal cell carcinoma (vhRCC): a retrospective study


10 Sep 2017


Poster display session


Cytotoxic Therapy;  Renal Cell Cancer


Matthew Campbell


Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371


M.T. Campbell1, M.A. Bilen2, C. Duran3, E. Altinmakas3, Z. Lim1, A. Shah1, E. Jonasch1, N. Tannir1

Author affiliations

  • 1 Genitourinary Medical Oncology, MD Anderson Cancer Center, 77030 - Houston/US
  • 2 Hematology And Medical Oncology, Winship Cancer Institute of Emory University, 30322 - Atlanta/US
  • 3 Diagnostic Imaging, MD Anderson Cancer Center, 77030 - Houston/US


Abstract 2762


Cabozantinib (C) prolongs overall survival (OS) and progression-free survival (PFS) in patients with metastatic clear-cell renal cell carcinoma (ccRCC) that progressed on first-line VEGFR-TKI. No standard of care systemic therapy exists for the management of patients with metastatic vhRCC.


This is a retrospective, IRB approved study of patients with vhRCC who received cabozantinib at MD Anderson Cancer Center from January 2014-January 2017. Information collected from the medical records included the baseline characteristics, toxicity, dose reductions, and OS. A blinded radiologist assessed the radiographic response using RECIST v1.1. Descriptive statistics, the Kaplan Meier method and the log rank test were applied using Microsoft Excel and GraphPad Prism version 6 software.




N = 30
GenderMale = 26 (86.7%)
Age, median (range)58.4 years (25-81)
Prior Nephrectomy27 (90%)
HistologyPapillary (P) 17 Chromophobe (Chr) 6 Other: unclassified 3, translocation 2, sarcomatoid (sarc) 1, mucinous tubular/spindle cell 1
Prognostic Risk Group MSKCC IMDCGood/Intermediate/Poor 2/20/8 2/23/5
Number of Prior Therapies 0 1 >1 Median (range) Previous VEGFR Tyrosine Kinase Inhibitor3 7 20 2 (0-5) 26

Median PFS was 8.6 months (mos) (95%CI: 6.1-14.7), and median OS was 22.7 mos (95%CI:10.8-NR), median follow up 10.6 months (95%CI: 7.1-14.1). There were no significant differences detected between patients with papillary versus non-papillary histologies with respect to PFS or OS. At last follow up, 13 patients remain on treatment with median time on therapy for all patients of 15.0 months. Of the 28 patients with measurable disease, there were 4 confirmed PRs (2 P, 1 Chr, 1 unclassifed) for a 14% ORR. For the entire cohort, 20 of 30 (66.7%) with stable disease, and 6 of 30 with progressive disease (20%), for a disease control rate of 24 of 30 (80%). Of 21 patients who started C at 60 mg/d, 12 (57%) required dose reduction due to toxicity. Multiple patients required treatment breaks but none discontinued therapy due to toxicity.


In this retrospective study, C produced a clinically meaningful benefit in patients with metastatic vhRCC, the majority of whom had PD on prior VEGFR-TKIs. Prospective trials of C in vhRCC are warranted and planned.

Clinical trial identification

Legal entity responsible for the study

Matthew T Campbell




M.T. Campbell: Serve on advisory boards for Eisai and AstraZeneca. M.A. Bilen: Advisory board for Exelixis. N. Tannir: Served as a consultant and has served on advisory board for Exelixis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.